# Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

> **NCT00293332** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 1 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00293332
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2007-03
- **Final completion:** 2007-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to low subject accrual
- **Last updated:** 2011-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293332, "Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT00293332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*